⁶⁸Ga-FAPI PET/CT分期对胃癌和结直肠癌生存获益优于CE-CT和¹⁸F-FDG PET/CT
这项单中心回顾性研究分析了2021年3月至2023年3月间未经治疗的胃癌或结直肠癌患者270例(胃癌137例、结直肠癌133例),比较⁶⁸Ga-FAPI PET/CT与CE-CT、¹⁸F-FDG PET/CT分期的生存获益。中位随访3.02年(95%CI: 2.7-3.3年),⁶⁸Ga-FAPI PET/CT分期患者中位OS显著长于CE-CT或¹⁸F-FDG PET/CT分期患者(结直肠癌p=0.0123;胃癌p=0.037),并提高分期准确性、改变41%-52%患者的分期、减少42%-69%的不必要手术。
要点
- ⁶⁸Ga-FAPI PET/CT分期患者中位OS显著优于CE-CT或¹⁸F-FDG PET/CT分期患者。
- ⁶⁸Ga-FAPI PET/CT改变41%-52%患者的分期,减少42%-69%的不必要手术。
- 多因素Cox回归显示CE-CT和¹⁸F-FDG PET/CT相对于⁶⁸Ga-FAPI PET/CT为预后风险因素。
核心结论
- 胃癌或结直肠癌患者采用⁶⁸Ga-FAPI PET/CT分期,相比CE-CT或¹⁸F-FDG PET/CT分期,疾病进展和生存结局均有改善。
研究设计与样本
- 单中心回顾性研究,纳入2021年3月至2023年3月未经治疗的胃癌或结直肠癌患者270例(胃癌137例、结直肠癌133例),比较三种影像诊断模式的分期准确性、不必要手术减少、PFS和OS。
主要发现
- 中位随访3.02年(95%CI: 2.7-3.3年),患者分组基线特征可比。
- 结直肠癌患者中⁶⁸Ga-FAPI PET/CT分期者中位OS显著长于CE-CT或¹⁸F-FDG PET/CT分期者(p=0.0123)。
- 胃癌患者中⁶⁸Ga-FAPI PET/CT分期者中位OS显著长于CE-CT或¹⁸F-FDG PET/CT分期者(p=0.037)。
- ⁶⁸Ga-FAPI PET/CT提高分期准确性,改变41%-52%患者的分期,减少42%-69%的不必要手术。
- Cox多因素回归识别CE-CT和¹⁸F-FDG PET/CT相对于⁶⁸Ga-FAPI PET/CT为预后风险因素。
临床怎么用
- 对胃癌或结直肠癌患者,可考虑采用⁶⁸Ga-FAPI PET/CT进行分期以优化治疗决策。
局限性
- 本研究为单中心回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this retrospective study was to investigate whether gallium-68-labeled fibroblast activation protein inhibitor (⁶⁸Ga-FAPI) positron emission tomography/computed tomography (PET/CT) that provided altered staging and adjusted treatment decisions was more effective for prolonging patient survival compared to that achieved by either contrast-enhanced computed tomography (CE-CT) or fluorine-18-fluorodeoxyglucose (¹⁸F-FDG) PET/CT. METHODS: We analyzed patients diagnosed with untreated gastric or colorectal cancer between March 2021 and March 2023 who were staged using these three imaging diagnostic modes described above. The accuracy of staging, reduction of unnecessary surgery, progression-free survival (PFS), and overall survival (OS) were used as the main comparative indicators. The potential independent risk factors affecting the prognosis of patients with gastric or colorectal cancer were also analyzed. RESULTS: A total of 270 patients (137 gastric and 133 colorectal cancers) were enrolled, with a median follow-up of 3.02 years (95%CI: 2.7-3.3 years). The baseline characteristics of the patient groups were comparable. For both cancers, patients staged by ⁶⁸Ga-FAPI PET/CT had significantly longer median OS than those staged by either CE-CT or ¹⁸F-FDG PET/CT (colorectal cancer: p = 0.0123; gastric cancer: p = 0.037). ⁶⁸Ga-FAPI PET/CT also improved the accuracy of staging and altered staging in 41%-52% of patients, with a reduction in unnecessary surgeries of 42%-69%. Cox multivariate regression identified CE-CT and ¹⁸F-FDG PET/CT as prognostic risk factors relative to ⁶⁸Ga-FAPI PET/CT. CONCLUSION: In patients with gastric or colorectal cancer, those who underwent staging with 68Ga‑FAPI PET/CT showed improvements in disease progression and survival outcomes compared with those staged with either CE‑CT or 18F‑FDG PET/CT. The underlying mechanisms of these improvements may be related to increased staging accuracy and the subsequent selection of less invasive therapeutic strategies. These findings highlight the clinical value of 68Ga‑FAPI PET/CT in these patient populations. (Trial registration: ChiCTR ChiCTR2400081233. Registered 27 February 2024).
引用
- Wu X, Ma L, Zhao Y, et al. Survival benefit of ⁶⁸Ga-FAPI PET/CT staging for prognostic assessment in gastric and colorectal cancer compared with CE-CT and ¹⁸F-FDG PET/CT: a single-center retrospective study. Eur J Nucl Med Mol Imaging. 2026. PMID: 42277430. doi:10.1007/s00259-026-07991-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。